CN-122012317-A - Cat-origin lactobacillus strain and application thereof

Abstract

The invention discloses a cat-source lactobacillus strain and application thereof, belonging to the field of microbial preparations. The invention screens and obtains a cat source probiotics strain with excellent characters, namely Pediococcus acidilactici G91, from healthy kittens. The strain not only passes through the severe digestive tract environment simulation screening of acid resistance and bile salt resistance, but also shows excellent self-aggregation capability, surface hydrophobicity, cell adhesion capability, bacteriostasis capability and other core probiotics. Further biological identification and hemolytic performance and drug sensitivity measurement prove that the strain is safe pediococcus acidilactici which is free of hemolysis and sensitive to antibiotics, G91 can promote the growth and development of seedlings, improve intestinal barrier and function, regulate intestinal flora and immune system, effectively resist salmonella constant value and infection, has excellent probiotic performance, is an ideal strain resource for developing microecological preparations for cats, and provides a safe and efficient novel microecological product and technical scheme for healthy cultivation and disease prevention of pet cats.

Inventors

• WANG JIANZHONG
• He Huaiyue
• LI JINMAN
• XUE XIU
• WU DANNI
• HU JINGTAO
• WANG CHUNFENG

Assignees

• 吉林农业大学

Dates

Publication Date

20260512

Application Date

20260123

Claims (10)

1. 1. A cat-source lactobacillus strain is characterized in that the strain is Pediococcus acidilactici G91, is named Pediococcus ACIDILACTICI G91 and is preserved in China center for type culture Collection (China, university of Wuhan, and post code: 430072, with a preservation number of CCTCC NO: M20252885, at 12 months and 15 days 2025.
2. 2. Use of the feline lactobacillus strain of claim 1 for the preparation of a feline microecological formulation.
3. 3. Use of the feline lactobacillus strain of claim 1 for the preparation of a medicament against salmonella infection.
4. 4. A cat source probiotic formulation comprising the cat source lactobacillus strain of claim 1 and a pharmaceutically acceptable carrier.
5. 5. The cat-source microecological formulation according to claim 4, wherein the viable count of Pediococcus acidilactici G91 in the formulation is 1X 10 9 CFU/mL.
6. 6. Use of a cat source probiotic according to claim 4, for the preparation of a formulation for promoting cat growth, reducing the feed to weight ratio or modulating cat intestinal development and flora structure.
7. 7. Use of a cat-derived probiotic according to claim 4, for the preparation of a formulation for increasing the immune function of a cat, wherein said increasing the immune function comprises increasing the interleukin-10 and secretory immunoglobulin a content in the serum and/or decreasing the interleukin-6 content in the serum.
8. 8. An antibacterial diarrhea drug for cats, comprising the feline lactobacillus strain of claim 1 and a pharmaceutically acceptable carrier.
9. 9. The anti-salmonella infection medicament for cats according to claim 8, wherein the viable count of pediococcus acidilactici strain G91 in the medicament is 1 x 10 9 CFU/mL.
10. 10. The anti-salmonella infection medicament for cats of claim 8, wherein the anti-salmonella infection comprises a prophylactic or adjuvant treatment in the form of a reduction in intestinal tissue damage and a reduction in liver load.

Description

Cat-origin lactobacillus strain and application thereof Technical Field The invention relates to the field of microbial preparations, in particular to a cat-source lactobacillus strain and application thereof in microecological preparations and anti-salmonella infection medicines. Background With the rapid development of the pet industry, the health and welfare of domestic cats are increasingly concerned. During the feeding of cats, digestive system health is a central factor affecting their quality of life and disease resistance. However, domestic cats often suffer from disturbed intestinal flora due to factors such as changes in dietary structure, environmental stress, antibiotic abuse, etc., which in turn lead to a series of health problems such as diarrhea, constipation, dyspepsia, and reduced immunity. Diarrhea, one of the clinically common symptoms of cats, can occur at various ages, with bacterial intestinal infections caused by salmonella, campylobacter, etc. being an important cause. The diseases not only affect nutrition absorption, but also can cause dehydration, electrolyte disturbance and bloody stool, and even endanger life when serious. At present, the treatment for cat bacterial enteritis still takes antibiotics as the main component, but the problems of intestinal flora disorder, drug resistance increase and the like are easily caused by long-term or improper use, and the simple dependence on antibacterial drugs is a passive and limited coping strategy. Therefore, the development of a safe and effective novel prevention and treatment means is particularly urgent. Probiotics are a group of active microorganisms that have beneficial effects on host health and are widely found in humans and animals. The species are various and include various bacteria such as Lactobacillus spp, bifidobacterium spp, bacillus spp, and Enterococcus spp. Among them, lactic acid bacteria are important groups of probiotics, including hundreds of species such as lactobacillus acidophilus, lactobacillus fermentum, lactobacillus reuteri, etc., and have good potential in regulating intestinal health due to their characteristics of acid production, pathogen inhibition, barrier function enhancement, etc. However, the effect of probiotics is remarkable in host specificity, i.e. strains derived from the host are more likely to localize and function in their intestinal tracts. The animal microecological preparation (Microbial Ecological Agents, MEA) is a product which is based on the microecological principle and can be used for improving the health level of animals by supplementing beneficial living bacteria or metabolites thereof and regulating intestinal microecological balance. The effect core is that probiotics regulate and control the gastrointestinal microenvironment. The gastrointestinal tract of cats has complex and unique microflora, mainly anaerobic and facultative anaerobes, with a significant difference in flora composition, abundance and diversity from humans or other animals. Studies have shown that the feline intestinal flora is individual-specific and relatively stable, further emphasizing the importance of "strain-host" adaptation. At present, commercial pet probiotics products are various, but aiming at the problems that the development of excellent cat source lactobacillus strains is relatively insufficient, most products use human or non-cat source strains, and the species difference can cause low field planting rate, unstable effect and the like. Therefore, the method screens the special lactobacillus strain which is derived from the intestinal tract of a healthy cat and has excellent probiotics characteristics, and develops the microecological preparation for the cat by taking the strain as a core, thereby having important significance for more accurately and effectively maintaining the intestinal tract health of the cat and reducing the antibiotic dependence. Disclosure of Invention The invention aims at obtaining a probiotic strain of animal origin with excellent properties, firstly collecting an anus swab of a healthy kitten, separating 153 strains of lactic acid bacteria by using an MRS broth culture medium, respectively evaluating biological properties of lactobacillus rhamnosus LGG (Lactobacillus rhamnosus GG) which is widely applied in clinic as a contrast, such as self-aggregation capability, surface hydrophobicity, cell adhesion capability, bacteriostasis capability and the like, screening out a strain G91 with the best properties, and identifying the strain as Pediococcus acidilactici by using gram staining, biochemical identification and molecular biological methods. The identification results of hemolysis and drug sensitivity show that the strain has no safety risk and is an ideal strain resource for developing microecological preparations for cats. The strain G91 is named as Pediococcus acidilactici G91 (Pediococcus acidilacticiG 91) and is preserved in China center for type culture Collec